Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Medigen Vaccine Biologics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -54.88%.
The industry rank for Medigen Vaccine Biologics's 3-Year RORE % or its related term are showing as below:
ROCO:6547's 3-Year RORE % is ranked worse than 83.63% of 1289
companies
in the Biotechnology industry
Industry Median: -11.55
vs ROCO:6547: -54.88
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Medigen Vaccine Biologics 3-Year RORE % Related Terms
Medigen Vaccine Biologics 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, RVMD: 3-Year RORE % Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Medigen Vaccine Biologics (ROCO:6547) has a 3-Year RORE % of -54.88 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Medigen Vaccine Biologics and its competitors. According to the industry distribution chart, Medigen Vaccine Biologics ranks #1078 out of 1289 companies in the Biotechnology industry, placing it in the top 83.6%.
Is Medigen Vaccine Biologics' 3-Year RORE % too high?
Medigen Vaccine Biologics' current 3-Year RORE % is -54.88. Based on the distribution chart, Medigen Vaccine Biologics ranks #1078 out of 1289 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medigen Vaccine Biologics has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #1078 out of 1289 companies for 3-Year RORE %. This places Medigen Vaccine Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Medigen Vaccine Biologics and its competitors. Medigen Vaccine Biologics's current 3-Year RORE % is -54.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$57.59, compared to a current price of NT$47.35 — trading 17.8% below its estimated fair value. The current 3-Year RORE % is -54.88. Medigen Vaccine Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current 3-Year RORE % is -54.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued.
The current stock price of NT$47.35 is trading 17.8% below its estimated GF Value™ of NT$57.59.
GuruFocus considers Medigen Vaccine Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:6547:
3-Year RORE %: -54.88
GF Value™: NT$57.59 vs. price of NT$47.35 (17.8% below fair value)
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
68GF Score
Get the complete analysis for ROCO:6547
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
